<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, and transplant numbers have increased five-fold during the last decade </plain></SENT>
<SENT sid="1" pm="."><plain>Only a few controlled prospective studies are available, and different opinions prevail </plain></SENT>
<SENT sid="2" pm="."><plain>Data from 118 167 HSCT (36% allogeneic, 64% autologous) collected within the EBMT activity survey from 1990 to 2001 were used to assess trends over time, transplant rates and coefficient of variation (CV) of transplant rates among European countries for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; 18.5%), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL; 12%), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; 11.5%), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 3%), <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (LPS; 36.3%) and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM; 18.7%) </plain></SENT>
<SENT sid="3" pm="."><plain>Transplant rates increased in <z:hpo ids='HP_0000001'>all</z:hpo> countries and for <z:hpo ids='HP_0000001'>all</z:hpo> indications from 1990 to 2001 from 1.7-fold (<z:mp ids='MP_0005481'>CML</z:mp>) to 24.8-fold (MM) </plain></SENT>
<SENT sid="4" pm="."><plain>Transplant rates have declined for <z:mp ids='MP_0005481'>CML</z:mp> since 1999 </plain></SENT>
<SENT sid="5" pm="."><plain>Autologous HSCT are the preferred choice for LPS and MM, allogeneic HSCT for ALL and <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>CVs of less than 50% suggest consensus for allogeneic HSCT in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, ALL, <z:mp ids='MP_0005481'>CML</z:mp>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and NHL, for autologous HSCT in LPS and MM </plain></SENT>
<SENT sid="7" pm="."><plain>These data give an overview of the current status of HSCT for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> in Europe and provide objective information for health-care providers and patient counselling </plain></SENT>
</text></document>